Eloxx Pharmaceuticals (NASDAQ:ELOX) Posts Earnings Results

Eloxx Pharmaceuticals (NASDAQ:ELOX) posted its earnings results on Tuesday. The company reported ($0.66) earnings per share for the quarter, Zacks reports.

Eloxx Pharmaceuticals Stock Up 12.8%

Shares of NASDAQ:ELOX traded up $2.18 during trading on Tuesday, hitting $19.18. The company’s stock had a trading volume of 51,268 shares, compared to its average volume of 57,978. The stock has a market capitalization of $13.20 million, a P/E ratio of -1.25 and a beta of -1,864.08. Eloxx Pharmaceuticals has a fifty-two week low of $8.20 and a fifty-two week high of $19.96. The firm’s 50-day simple moving average is $16.23.

Analyst Ratings Changes

A number of research analysts have commented on the company. Guggenheim started coverage on Eloxx Pharmaceuticals in a research note on Monday, July 20th. They set a “buy” rating and a $43.00 price objective on the stock. Lifesci Capital assumed coverage on Eloxx Pharmaceuticals in a research report on Wednesday, July 22nd. They set an “outperform” rating and a $40.00 price target on the stock. Finally, Wall Street Zen raised shares of Eloxx Pharmaceuticals to a “hold” rating in a research report on Saturday, August 1st. Two research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Eloxx Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $41.50.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.